ArticleJournal of neuro-oncology2025
Identification of NEK6 as a potential biomarker for prognosis in glioma and its functional implications.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeNever in mitosis gene A-related kinase 6 (NEK6) is involved in mitotic cell cycle. The objective of the present study is to comprehensively explore the prognostic value of NEK6 and its potential functions in multiple cancers, especially in gliomas.
methodsWe performed comprehensive analyses of NEK6 in pan-cancer, including expression profile, immune characteristics and its relationship with clinical prognosis. Moreover, we validated our significant conclusions through multiple cell experiments (such as clone formation assay, MTT assay and flow cytometry) and analyses based on clinical samples (such as immunohistochemistry analysis).
resultsNEK6 was significantly upregulated in gliomas. And our study indicated that the increased level of NEK6 was associated with poor clinical prognoses of patients. The single-cell analysis revealed that NEK6 overexpression was highly related to malignant cells and Mono/Macrophages (denoted as the monocyte and macrophage population) in glioma tissue. The decrease in NEK6 hindered the growth and migration capacity of the glioma cells, leading to a halt in the G2/M phase of the cell cycle and triggering apoptosis.
conclusionTaken together, our data uncovered the prognostic value, therapeutic potential, and molecular insight of NEK6 in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.